Evidence map›Paper›PMID 40487692›Full record

ArticleActa crystallographica. Section E, Crystallographic communications2025

Synthesis, crystal structure and Hirshfeld surface analysis of 1,1'-[oxybis(ethane-2,1-di-yl)]bis-(2-methyl-sulfanyl-1

Ahmed Moussaif, Lhoussaine El Ghayati, Camille Kalonji Mubengayi, Abdulsalam Alsubari, El Mokhtar Essassi, Joel T Mague, Youssef Ramli

Abstract read
In one paragraph

Article in Acta crystallographica. Section E, Crystallographic communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Crystal structure and Hirshfeld surface analysis of 2,6-bis-[1-(prop-2-yn-1-yl)-1Acta crystallographica. Section E, Crystallographic communications · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ahmed MoussaifNational Center for Nuclear Energy, Science and Technology,Rabat Morocco.ORCID https://orcid.org/0000-0001-8444-0537
Lhoussaine El GhayatiLaboratory of Heterocyclic Organic Chemistry Medicines Science Research Center Pharmacochemistry Competence Center Mohammed V University in Rabat Faculte des Sciences Av Ibn Battouta BP 1014 Rabat Morocco.
Camille Kalonji MubengayiLaboratoire de Chimie et Biochimie, Institut Superieur des Techniques Medicales, Kinshasa, Republique Democratique, Congo.
Abdulsalam AlsubariLaboratory of Medicinal Chemistry, Faculty of Clinical Pharmacy, 21 September University, Yemen.
El Mokhtar EssassiLaboratory of Heterocyclic Organic Chemistry Medicines Science Research Center Pharmacochemistry Competence Center Mohammed V University in Rabat Faculte des Sciences Av Ibn Battouta BP 1014 Rabat Morocco.
Joel T MagueDepartment of Chemistry, Tulane University, New Orleans, LA 70118, USA.ORCID https://orcid.org/0000-0003-3488-1945
Youssef RamliLaboratory of Medicinal Chemistry Drug Sciences Research Center Faculty of Medicine and Pharmacy Mohammed V University in Rabat Morocco.ORCID https://orcid.org/0000-0002-6885-5692

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The asymmetric unit of the title compound, C

Indexed as

benzimidazoleC—H⋯π(ring) inter­actionscrystal structurehydrogen bondthio­etherπ-stacking

Identifiers

PMID40487692
PMCPMC12142410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.